Skip to main content
. 2019 Jul 2;12(9):1213–1220. doi: 10.1016/j.tranon.2019.05.015

Figure 2.

Figure 2

Associations of mtDNA79, mtDNA230 and the mtDNA integrity with FIGO stages, lymph node status and postoperative tumor residue. (A) The box plots compare the levels of mtDNA79, mtDNA230 and the mtDNA integrity in healthy women (n = 60) and the patients with FIGO I-II (n = 50), III (n = 78) and IV (n = 36). ROC analyses show the profiles of sensitivities and specificities of (B) mtDNA79, mtDNA230 and (C) the mtDNA integrity to distinguish healthy control group from patients with FIGO I-II. (D) The box plots compare the levels of mtDNA79, mtDNA230 and the mtDNA integrity in the serum of healthy women (n = 60), lymph-node negative patients (N0, n = 57) and lymph-node positive patients (N1, n = 81). (E) The box plots compare the levels of mtDNA79, mtDNA230 and the mtDNA integrity in the serum of healthy women (n = 60), EOC patients without (n = 104) and with (n = 54) tumor residue after operation. *P < .05, **P < .01.